Literature DB >> 22907419

The effect of metal-chelating polymers (MCPs) for 111In complexed via the streptavidin-biotin system to trastuzumab Fab fragments on tumor and normal tissue distribution in mice.

Amanda J Boyle1, Peng Liu, Yijie Lu, Dirk Weinrich, Deborah A Scollard, Ghislaine Ngo Njock Mbong, Mitchell A Winnik, Raymond M Reilly.   

Abstract

PURPOSE: To study the effects of backbone composition and charge of biotin-functionalized metal-chelating polymers (Bi-MCPs) for (111)In complexed to streptavidin (SAv)-trastuzumab Fab fragments on tumor and normal tissue localization.
METHODS: Bi-MCPs were synthesized with a polyacrylamide [Bi-PAm(DTPA)(40)], polyaspartamide [Bi-PAsp(DTPA)(33)] or polyglutamide [Bi-PGlu(DTPA)(28)] backbone and harboured diethylenetriaminepentaacetic acid (DTPA) chelators for (111)In. Bi-PAm(DTPA)(40) had a net negative charge; Bi-PAsp(DTPA)(33) and Bi-PGlu(DTPA)(28) were zwitterionic with a net neutral charge. Binding to HER2+ SKOV-3 human ovarian carcinoma cells was determined. Tissue uptake was studied in Balb/c mice by MicroSPECT/CT imaging and biodistribution studies. Tumor and normal tissue uptake of (111)In-labeled Bi-PAsp(DTPA)(33) or Bi-PGlu(DTPA)(28) complexed to SAv-Fab was evaluated 48 h post-injection in athymic mice with subcutaneous SKOV-3 xenografts.
RESULTS: SAv-Fab complexed to MCPs bound specifically to SKOV-3 cells; but specific binding was decreased 2-fold. Liver uptake was 5-13 fold higher for Bi-PAm(DTPA)(40) than Bi-PAsp(DTPA)(33) and Bi-PGlu(DTPA)(28) but was reduced by decreasing negative charges by saturation with indium. (111)In-Bi-PAsp(DTPA)(33) complexed to SAv-Fab accumulated in SKOV-3 tumors; low tumor uptake was found for (111)In-Bi-PGlu(DTPA)(28)-SAv-Fab.
CONCLUSIONS: Zwitterionic MCPs composed of polyaspartamide with a net neutral charge are most desirable for constructing radioimmunoconjugates.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22907419     DOI: 10.1007/s11095-012-0853-y

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  24 in total

1.  Curious results with palladium- and platinum-carrying polymers in mass cytometry bioassays and an unexpected application as a dead cell stain.

Authors:  Daniel Majonis; Olga Ornatsky; Robert Kinach; Mitchell A Winnik
Journal:  Biomacromolecules       Date:  2011-09-28       Impact factor: 6.988

2.  Anionic amino acid dendrimer-trastuzumab conjugates for specific internalization in HER2-positive cancer cells.

Authors:  Takuya Miyano; Wassana Wijagkanalan; Shigeru Kawakami; Fumiyoshi Yamashita; Mitsuru Hashida
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

Review 3.  Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

Authors:  Kate McKeage; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Block copolymer micelles target Auger electron radiotherapy to the nucleus of HER2-positive breast cancer cells.

Authors:  Bryan Hoang; Raymond M Reilly; Christine Allen
Journal:  Biomacromolecules       Date:  2012-01-17       Impact factor: 6.988

5.  HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb.

Authors:  Rameshwer Shukla; Thommey P Thomas; Jennifer L Peters; Ankur M Desai; Jolanta Kukowska-Latallo; Anil K Patri; Alina Kotlyar; James R Baker
Journal:  Bioconjug Chem       Date:  2006 Sep-Oct       Impact factor: 4.774

6.  The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles.

Authors:  Kai Xiao; Yuanpei Li; Juntao Luo; Joyce S Lee; Wenwu Xiao; Abby M Gonik; Rinki G Agarwal; Kit S Lam
Journal:  Biomaterials       Date:  2011-02-04       Impact factor: 12.479

7.  Stability constants for Gd3+ binding to model DTPA-conjugates and DTPA-proteins: implications for their use as magnetic resonance contrast agents.

Authors:  A D Sherry; W P Cacheris; K T Kuan
Journal:  Magn Reson Med       Date:  1988-10       Impact factor: 4.668

Review 8.  Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions.

Authors:  R M Reilly; J Sandhu; T M Alvarez-Diez; S Gallinger; J Kirsh; H Stern
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

9.  Biodistribution of anti-CEA F(ab')2 fragments conjugated with chelating polymers: influence of conjugate electron charge on tumor uptake and blood clearance.

Authors:  M A Slinkin; C Curtet; A Faivre-Chauvet; C Sai-Maurel; J F Gestin; V P Torchilin; J F Chatal
Journal:  Nucl Med Biol       Date:  1993-05       Impact factor: 2.408

10.  A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT.

Authors:  Conrad Chan; Deborah A Scollard; Kristin McLarty; Serena Smith; Raymond M Reilly
Journal:  EJNMMI Res       Date:  2011-08-17       Impact factor: 3.138

View more
  3 in total

1.  Trastuzumab labeled to high specific activity with ¹¹¹In by conjugation to G4 PAMAM dendrimers derivatized with multiple DTPA chelators exhibits increased cytotoxic potency on HER2-positive breast cancer cells.

Authors:  Conrad Chan; Zhongli Cai; Raymond M Reilly
Journal:  Pharm Res       Date:  2013-04-25       Impact factor: 4.200

Review 2.  Nanostructures as Radionuclide Carriers in Auger Electron Therapy.

Authors:  Nasrin Abbasi Gharibkandi; Joanna Gierałtowska; Kamil Wawrowicz; Aleksander Bilewicz
Journal:  Materials (Basel)       Date:  2022-02-01       Impact factor: 3.623

3.  Polymeric dipicolylamine based mass tags for mass cytometry.

Authors:  Yefeng Zhang; Peng Liu; Daniel Majonis; Mitchell A Winnik
Journal:  Chem Sci       Date:  2022-02-23       Impact factor: 9.825

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.